Trial · NCT03374254
Adverse events4,806
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 4,806
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Cohort A Part 1: Pembrolizumab +Binimetinib 30 mg | 1 | 6 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort A Part 1: Pembrolizumab +Binimetinib 45 mg | 2 | 14 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort B Part 1: Pembrolizumab + mFOLFOX7 | 4 | 15 | 7 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort B Part 2: Pembrolizumab + mFOLFOX | 5 | 16 | 9 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort C Part 1: Pembrolizumab + mFOLFOX7 + Binimetinib 30 mg | 3 | 11 | 4 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort D Part 1: Pembrolizumab + FOLFIRI | 9 | 16 | 21 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort D Part 2: Pembrolizumab + FOLFIRI | 3 | 16 | 3 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort E Part 1: Pembrolizumab + FOLFIRI + Binimetinib 30 mg | 5 | 9 | 7 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort E Part 1: Pembrolizumab + FOLFIRI + Binimetinib 45 mg | 4 | 11 | 5 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cohort A Part 1: Pembrolizumab +Binimetinib 30 mg | 0 | 6 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cohort A Part 1: Pembrolizumab +Binimetinib 45 mg | 0 | 14 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cohort B Part 1: Pembrolizumab + mFOLFOX7 | 0 | 15 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cohort B Part 2: Pembrolizumab + mFOLFOX | 2 | 16 | 2 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cohort C Part 1: Pembrolizumab + mFOLFOX7 + Binimetinib 30 mg | 0 | 11 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cohort D Part 1: Pembrolizumab + FOLFIRI | 0 | 16 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cohort D Part 2: Pembrolizumab + FOLFIRI | 0 | 16 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cohort E Part 1: Pembrolizumab + FOLFIRI + Binimetinib 30 mg | 0 | 9 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cohort E Part 1: Pembrolizumab + FOLFIRI + Binimetinib 45 mg | 0 | 11 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | Cohort A Part 1: Pembrolizumab +Binimetinib 30 mg | 0 | 6 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | Cohort A Part 1: Pembrolizumab +Binimetinib 45 mg | 0 | 14 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03374254/events